The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
Increasing Precision in Cancer Cell Death to Prevent Metastasis In housework and lawn work, it is important to have the right tool for the job.
Mark A. Lewis, MD, Director of Gastrointestinal Oncology, Intermountain Healthcare, Utah, has joined the Board of Directors for the Neuroendocrine Tumor Research Foundation. Dr. Lewis,
NETRF given the highest ranking for financial responsibility and transparency by leading nonprofit rating program, GoldStar.
A few weeks ago, I heard Dr. James Allison, a scientist at MD Anderson Cancer Center and winner of the 2018 Nobel Prize for Physiology
NETRF invites your participation in a special, upcoming holiday. National Doctor’s Day will be celebrated on Saturday, March 30th and it is a great opportunity
When I look back on 2018, I see tremendous growth and progress in the field of NETs and in NETRF. We are proud of our
2018 was off to a game-changing start when the FDA approved Lutetium 177 dotatate for gastrointestinal and pancreatic NETs—the first PRRT radiopharmaceutical approved in the United States.
The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a
NETRF has launched a $10 million fundraising campaign, the largest of its kind in our history. Every gift we receive will be MATCHED, doubling our
NET Survivor Finds Hope and Inspiration That’s it—my number is up, Dave McCoy thought when he learned he had neuroendocrine cancer in 2008. A cancer, he